Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jun 1;103(1):61–72. doi: 10.1038/sj.bjc.6605699

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2010 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

(A) Pathological pattern of the peritoneum 20 days after OVCAR-3WT implantation. Nude mice bearing OVCAR-3 macroscopic ascites were treated with vehicle (A1) or trastuzumab at a dose of 150 μg ml per day (A2) administered by i.p. route for 72 h. Naive nude mice were i.p. injected once a day for 3 days with 1 ml of either RPMI-1640 (A3 control group) or the 24 h serum-free cleared supernatant collected from OVCAR-3 cells in culture (A4). Mice were killed and the peritonea were collected and formalin fixed. Microscopic examination was performed and pictures were taken. (B) Concentrations of 99^mTc-DTPA over time in the bladder: peritoneal permeability. 99^mTc-DTPA appeared in the bladder more intensively in treated animals compared with the untreated group. Arbitrary units express the 99^mTc-DTPA intensity detection in the region of interest (ROI) of the bladder (shortened by ‘B’ and by ‘P’ for the peritoneum:). ^*P<0.05. Student's t-test compared untreated group (control-ascites) with trastuzumab (TZ) treatment groups.